IRVINE, CA, and HERSTAL, BELGIUM – August 12, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH), a commercial-stage precision diagnostics company, today announced it will release its financial results for the second quarter and six-month period ended June 30, 2024, after market close on Wednesday, August 21, 2024.
| Title: | MDxHealth Presents Second Quarter and First Half 2024 Financial Results and Corporate Update Conference Call and Webcast |
| Speakers: | Michael K. McGarrity, Chief Executive Officer Ron Kalfus, Chief Financial Officer |
| Date: | August 21, 2024 |
| Time: | 4:30pm ET/ 22:30 CET |
| Conference Call Dial-in Details: | United States: 1-877-407-9716 Belgium: 0800 73 566 The Netherlands: 0800 022 3580 United Kingdom: 0 800 756 3429 |
| Conference ID: | 13747618 |
| Webcast: | https://viavid.webcasts.com/starthere.jsp?ei=1679031&tp_key=41436200eb |
The webcast should be accessed 15 minutes prior to the conference call start time. A replay of the webcast will be available following the conclusion of the live call and will be accessible on the Company’s website.
About MDxHealth
Mdxhealth is a commercial-stage precision diagnostics company that provides actionable molecular information to personalize patient diagnosis and treatment. The Company’s tests are based on proprietary genomic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis and prognosis of urologic cancers and other urologic diseases. The Company’s U.S. headquarters and laboratory operations are in Irvine, California, with additional laboratory operations in Plano, Texas. European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands. For more information, visit mdxhealth.com and follow us on social media at: www.twitter.com/mdxhealth, www.facebook.com/mdxhealth and www.linkedin.com/company/mdxhealth.
| MDxHealth This email address is being protected from spambots. You need JavaScript enabled to view it. | |
| LifeSci Advisors (IR & PR) US: +1 949 271 9223 This email address is being protected from spambots. You need JavaScript enabled to view it. |
NOTE: The mdxhealth logo, mdxhealth, Confirm mdx, Select mdx, Resolve mdx, Genomic Prostate Score, GPS and Monitor mdx are trademarks or registered trademarks of MDxHealth SA. The GPS test was formerly known as and is frequently referenced in guidelines, coverage policies, reimbursement decisions, manuscripts and other literature as Oncotype DX Prostate, Oncotype DX GPS, Oncotype DX Genomic Prostate Score, and Oncotype Dx Prostate Cancer Assay, among others. The Oncotype DX trademark, and all other trademarks and service marks, are the property of their respective owners.
| Last Trade: | US$2.19 |
| Daily Change: | -0.07 -3.10 |
| Daily Volume: | 82,123 |
| Market Cap: | US$108.400M |
November 06, 2024 October 14, 2024 September 25, 2024 August 21, 2024 | |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
